Baxter is a recognized leader in the manufacturing of quality medical products. The company’s manufacturing strength and commitment to quality are foundations of the company, building on more than 75 years of leadership in healthcare. Baxter’s manufacturing capabilities include automated filling of intravenous (IV) and dialysis solutions, production of administration sets and other devices, hardware and software manufacturing, pharmaceutical production, plasma fractionation and recombinant technology.
Baxter’s more than 50 manufacturing facilities in 26 countries enable the company to make products cost-effectively for local and regional markets. Baxter also is committed to quality and to using its proprietary technologies and synergistic manufacturing platforms to produce high-quality products with unmatched efficiency. More than half of Baxter’s 48,500 employees work in Baxter manufacturing plants worldwide.
As a leader in the production of IV and dialysis solutions and the tubing sets used to administer them, Baxter applies advanced technologies in extrusion and molding to keep quality high and costs competitive. Baxter also provides contract-manufacturing services to leading pharmaceutical companies to formulate and package their drugs in injectable vials and syringes. Baxter’s expertise in sterilization technologies is among the broadest in the industry, enabling the company to expand its portfolio with new drugs and biopharmaceuticals that require advanced sterilization methods.
Baxter continues to enhance its capabilities in the manufacture of hardware and software devices such as electronic IV infusion pumps and automated dialysis machines. Baxter also is a pioneer in plasma fractionation—the process of breaking down plasma into its component parts—and remains a leader in the production of safe and effective plasma-based therapies. Baxter also continues to expand its capabilities in recombinant manufacturing, producing the world’s leading recombinant factor VIII clotting factor for the treatment of hemophilia. In addition, Baxter’s proprietary “Vero cell” technology for manufacturing vaccines offers significant cost and productivity benefits over traditional egg-based vaccine production methods.
Baxter’s manufacturing operations work closely with the company’s research and development organization to bring new products to market. This includes addressing social and environmental issues across the product life cycle, from bioethics and sustainable design to efficient use of energy and materials. Manufacturing also works closely with the company’s global Quality and Supply Chain functions to ensure the safe, efficient and timely delivery of Baxter products to patients and clinicians worldwide.
Baxter’s worldwide manufacturing operations have a long-standing commitment to operational excellence and continuous improvement. Through the use of Lean manufacturing and other business excellence techniques, Baxter continuously improves the efficiency and effectiveness of its operations.
A number of Baxter facilities have received recognition for operational excellence. The Shingo Prize, one of the premier recognition programs for excellence in manufacturing, has been awarded to several facilities, most recently to the company’s Cartago, Costa Rica, plant in 2008. The Cartago facility was the first manufacturing operation to be awarded the Shingo Prize outside North America. Baxter’s North Cove facility in Marion, North Carolina, is the only two-time winner of the Shingo Prize. Baxter plants also have won other awards for quality excellence as well as for environmental, health and safety performance.
Qualifications for the many roles in manufacturing vary. In general, however, Baxter looks for the following: